ML19217A283: Difference between revisions
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
||
Line 30: | Line 30: | ||
XMAT451 Page 2 of 3 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | XMAT451 Page 2 of 3 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | ||
: 1. | : 1. | ||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | (for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | ||
: 2. | : 2. | ||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | (for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | ||
: 3. | : 3. | ||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | (for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | ||
: 4. | : 4. | ||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | (for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | ||
: 5. | : 5. | ||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | (for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | ||
: 6. | : 6. | ||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | (for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | ||
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | ||
: 1. | : 1. | ||
(for distribution to ultimate consignees) | (for distribution to ultimate consignees) | ||
XMAT451 Page 3 of 3 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | XMAT451 Page 3 of 3 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | ||
: 2. | : 2. | ||
(for distribution to ultimate consignees) | (for distribution to ultimate consignees) | ||
: 3. | : 3. | ||
(for distribution to ultimate consignees) | (for distribution to ultimate consignees) | ||
: 4. | : 4. | ||
(for distribution to ultimate consignees) | (for distribution to ultimate consignees) | ||
: 5. | : 5. | ||
(for distribution to ultimate consignees) | (for distribution to ultimate consignees) | ||
: 6. | : 6. | ||
(for distribution to ultimate consignees) | (for distribution to ultimate consignees) | ||
: 7. | : 7. | ||
(for distribution to ultimate consignees)}} | (for distribution to ultimate consignees)}} |
Latest revision as of 03:32, 2 February 2020
ML19217A283 | |
Person / Time | |
---|---|
Site: | 11006352 |
Issue date: | 08/02/2019 |
From: | Peter Habighorst NRC/OIP |
To: | Ionta G Cambridge Isotope Labs |
Savoy J | |
References | |
Download: ML19217A283 (3) | |
Text
EXPORT LICENSE NRC LICENSE NO.: XMAT451 United States of America Page 1 of 3 Nuclear Regulatory Commission NRC DOCKET NO.: 11006352 Washington, D.C. 20555 LICENSE EXPIRES: April 01, 2024 Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.
LICENSEE ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
Cambridge Isotope Laboratories, Inc. See following page(s) 50 Frontage Road Andover, MA 01810 Attn: Gary Ionta INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES) OTHER U.S. PARTY(IES) TO EXPORT See following page(s) Cambridge Istopoe Laboratories, Inc.
50 Frontage Road MA 01810 (supplier/distributor)
APPLICANT'S
REFERENCE:
Application Dated 3/27/2019 ULTIMATE DESTINATION: United Arab Emirates QUANTITY(IES) DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)
Deuterium in the form of deuterium oxide, deuterium gas, and other compounds.
10,000 kilograms Neither this license nor any right under this license shall be THIS LICENSE IS INVALID UNLESS SIGNED BELOW assigned or otherwise transferred in violation of the BY AUTHORIZED NRC REPRESENTATIVE provisions of the Atomic Energy Act of 1954, as Digitally signed by Peter J.
Peter J. Habighorst Habighorst amended, and the Energy Reorganization Act of 1974. SIGNATURE: Date: 2019.08.02 11:16:21 -04'00' Peter J. Habighorst, Acting Deputy Director This license is subject to the right of recapture or control NAME AND TITLE:
Office of International Programs by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of DATE OF ISSUANCE: August 02, 2019 the NRC.
EXPORT LICENSE
XMAT451 Page 2 of 3 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
- 1.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 2.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 3.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 4.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 5.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 6.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
- 1.
(for distribution to ultimate consignees)
XMAT451 Page 3 of 3 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
- 2.
(for distribution to ultimate consignees)
- 3.
(for distribution to ultimate consignees)
- 4.
(for distribution to ultimate consignees)
- 5.
(for distribution to ultimate consignees)
- 6.
(for distribution to ultimate consignees)
- 7.
(for distribution to ultimate consignees)